Pharmacokinetics, Pharmacodynamics, and Interactions & Cautions in Common Practice
Covering latest data as of February 2016 on Low Dose Naltrexone
Liberation of drugs from pharmaceutical formulation
Absorption of the drug into the bloodstream
Distribution of the drug in the body
Metabolism of the drug
Excretion of the drug from the body
Stephen is a pharmacist living in Glasgow. He is a superintendent pharmacist for 4 pharmacies – that means he provides advice on safety and clinical questions to the pharmacists he works with.
He got involved in LDN a while back, and has been an advocate of the therapy since meeting people very early on. "I had a friend with a really low immune cell count; no-one knew why it was happening. The doctors had tried everything they could think of to get it back up, to no avail- so I suggested she tried LDN. Remarkably, 2 weeks after starting the LDN her cell count was within normal range"
Although that example is not exactly to do with MS, Stephen says the example proved to him the clinical efficacy.
"It definitely does something - and if people are getting benefit from it, then why not try this? It is a lot less harmful than many of the other drugs used to treat MS. Just don't take it when you are on opiates, and check with your doctor or pharmacist first!"
"We fully support the trials that are getting underway - the faster we get double-blind placebo controlled studies, the faster everyone can get LDN on the NHS!"
Stephen is currently renovating an old house, running a church youth group and is also starting a new business - using fingerprint technology to safely identify patients.
Stephen said "Basically in my spare time - I sleep!"
Winner of the:
Royal Pharmaceutical Society Awards – 2012
“Leader in pharmacy”